MedPath

Avidhrt Clinical Equivalence Study

Not Applicable
Conditions
Equivalence of ECG Electrode Type Signal Quality for AF and Non AF Users
Interventions
Device: Avidhrt Sense Heart Monitor
Registration Number
NCT05357209
Lead Sponsor
Avidhrt Inc.
Brief Summary

The Avidhrt Clinical Equivalence Study will test and evaluate the equivalency between ECG signals acquired simultaneously using the Avidhrt Sense Lead-1 ECG, and an FDA cleared Lead-12 gel ECG. The Avidhrt Clinical Equivalence Study also includes a sub-study. The Avidhrt Sense Human Factors sub-study will evaluate the usability and efficacy of the user-interface of the Avidhrt Sense device.

Detailed Description

This study will test the clinical equivalency of an Avidhrt Sense acquired Lead-I ECG signal and a Lead-I ECG signal obtained from an FDA cleared 12-lead-ECG gel electrode.The Avidhrt Clinical Equivalence study is comprised of study Arm A and Arm B. In Arm A of this study the population is comprised exclusively of subjects with AF, who will be asked to participate in the Clinical Equivalence Study and in the Human Factors Sub-Study. In Arm B of this study the population will consist of all other subjects (no AF), who will be asked to participate in the Clinical Equivalence Study, with the option to enroll and participate in the Human Factors Sub-Study. This is a prospective, parallel-cohort, non-randomized study using an enriched population.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
75
Inclusion Criteria
  • Adults ≥ 22 years old at the time of enrollment
  • Capable of giving informed consent
  • Sufficient manual dexterity to capture an ECG using Avidhrt Sense
  • Subjects in the arrhythmia group must have a known history of arrhythmia, and may have an arrhythmia at the time of enrollment based on the screening ECG just before the study recordings are taken.
Exclusion Criteria
  • Cardiac pacemaker or implantable cardioverter-defibrillator
  • History of a life-threatening rhythm such as ventricular tachycardia or ventricular fibrillation
  • Anti-arrhythmic (rhythm control) medication use (such as amiodarone or flecainide)
  • Subjects in the normal controls group should not have any history of arrhythmia and should not be in arrhythmia at the time of enrollment based on the screening ECG
  • Subjects with tremors who are unable to stably hold the Avidhrt Sense during a recording without movement

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm AAvidhrt Sense Heart MonitorArm A of the Avidhrt study will contain subjects that have been/are diagnosed with AF. Arm A of the study will have the participants complete the Human Factors sub-study in addition to the primary clinical study.
Arm BAvidhrt Sense Heart MonitorArm B of the Avidhrt study will contain all other subjects (those non diagnosed with AF), and participants will receive the option whether to participate in the Human Factors sub-study.
Primary Outcome Measures
NameTimeMethod
Avidhrt Sense ECG equivalency12 months
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath